| Characteristics | Optimal LV lead position (n = 25) | Non-optimal LV lead position (n = 22) | p Value |
| Age (years), mean (SD) | 59 (10) | 58 (10) | 0.756 |
| Men/women | 17/8 | 14/8 | 0.995 |
| NYHA functional class, mean (SD) | 3.3 (0.4) | 3.2 (0.5) | 0.834 |
| Ischaemic cardiomyopathy, No (%) | 18 (72) | 16 (73) | 0.789 |
| QRS duration (ms), mean (SD) | 160 (20) | 157 (21) | 0.745 |
| LVEF (%), mean (SD) | 31 (6) | 30 (7) | 0.535 |
| LVGS (%), mean (SD) | 12.3 (2.0) | 11.5 (2.1) | 0.220 |
| Vo2max (ml/kg/min), mean (SD) | 14.2 (1.8) | 14.0 (2.1) | 0.841 |
| Concomitant treatment, No (%) | |||
| ACE inhibitors | 18 (72) | 16 (73) | 0.789 |
| ARBs | 5 (20) | 6 (27) | 0.811 |
| β Blockers | 22 (88) | 19 (86) | 0.790 |
| Digitalis | 12 (48) | 11 (50) | 0.883 |
| Diuretics | 8 (32) | 8 (36) | 0.995 |
| Aldosterone antagonists | 15 (60) | 14 (64) | 0.966 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; LVEF, left ventricular ejection fraction; LVGS, left ventricular global strain; NYHA, New York Heart Association; Vo2max, oxygen consumption at peak exercise.